Attractive valuation despite negative revisions

Strong insurance outcome and financials

Strong beat and outlook, but already priced in

DNB Bank ASA: 1 director

A director at DNB Bank ASA bought 5,000 shares at 261.000NOK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Strong beat from price increases impact

Stronger insurance and profit sharing

Heads-up for report 11 July

Heads-up for Q2-report, 11 July

Nordic non-life Q2e: A double tailwind

Recovery continues, but reflected in valuation

AUM rebound drives earnings growth

Norway: Best ideas Q2'25

Norwegian banks: Q1'25 outcome vs. expectations

Nordic non-life insurance – Q1 reporting wrap

Priced for flat interest rates: down to SELL

Svenska Handelsbanken AB - Mergers & Acquisitions (M&A), Partnerships ...

Summary Marketline's Svenska Handelsbanken AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Svenska Handelsbanken AB - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances a...

Insurance trip: 16 insurers in three days

Non-life have price increases > inflation in all markets, most in Norway. Life insurance growth with rapid growth & dividend payments. Prefer ALMB, Sampo, Solid, Tryg among non-life; STB for life

Delivers in-line with expectations

Adj. PTP -1% vs. ABGSCe & cons, driven by mgmt loan loss overlay; Trimmed lending guiding and positive capital revisions; Cons. up for 25e (beat), minor for '26e-'27e, stock to hold up

Large upside despite negative revisions

ROE held back by too-high capital base